Ask AI
ProCE Banner Activity

Entering a New Era: Evolving Precision Oncology in Pancreatic Cancer

Clinical Thought

Targeted therapies are beginning to reshape the treatment landscape beyond conventional chemotherapy in pancreatic cancer. In this commentary, experts address how practice-changing advances in KRAS inhibition, like daraxonrasib, will impact treatment sequencing paradigms, their recommended approaches to managing key adverse events with this new therapy, and how our increasing understanding of resistance mechanisms along with the growing importance of biomarker-driven treatment selection for an expanding targeted therapy pipeline are poised to improve outcomes for patients with metastatic and locally advanced disease.

Released: July 29, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education, in partnership with the Pancreatic Cancer Action Network (PanCAN).

ProCE Banner

Supporters

Supported by educational grants from Novocure and Revolution Medicines, Inc.

Novocure

Revolution Medicines, Inc.

Partners

Pancreatic Cancer Action Network (PanCAN)

ProCE Banner

Target Audience

This program is designed for community oncologists, advanced practice providers, oncology nurses, pharmacists, and other healthcare professionals involved in the multidisciplinary care of patients with pancreatic cancer across all disease stages, aiming to improve frontline and later-line treatment outcomes.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Assess emerging biomarker and molecular profiling data to guide personalized treatment decisions that incorporate novel therapeutic modalities

  • Select frontline and subsequent therapies for pancreatic cancer using current clinical evidence and guideline-based criteria, tailored to disease stage, patient performance status, and molecular biomarker profiles

  • Implement practical dose modification, toxicity monitoring, and supportive care strategies to manage gastrointestinal, hematologic, and neuropathic adverse events associated with pancreatic cancer therapies

Financial Disclosures

Primary Author

Efrat Dotan, MD, MTR: consultant/advisor/speaker: AbbVie, Amgen, Jazz, Lutris, Merck, Merus; researcher: AstraZeneca, Bristol Myers Squibb, Ipsen.

Andrew H. Ko, MD, FASCO: researcher: Apexigen, Arcus, Astellas, Bristol Myers Squibb, Crystal Genomic, Leap Therapeutics, Novartis, Revolution Medicines, Roche/Genentech, Verastem; consultant/advisor/speaker: Astellas, Corcept, Gilead, Jazz, Legend Biotech, Merus, Pfizer, Renovo, Revolution Medicines, Tango Therapeutics.

Paul E. Oberstein, MD, MS: consultant/advisor/speaker: Ipsen, Lilly, Revolution Medicine, Tango Therapeutics.

Additional Disclosures

Generative artificial intelligence (AI) tools were used for data analysis or summarization influencing content; revising or refining educational content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.